• Clinical Insights

Webinar: Overcoming Barriers to Medication Adherence Amid COVID-19 and Beyond

Apr 28th, 2021

Addressing the Challenges of Medication Adherence Amid COVID-19

A recent survey by the Centers for Disease Control and Prevention found that the proportion of U.S. adults with symptoms of anxiety and/or depression has tripled since the start of the pandemic. With that rise comes many challenges, including a greater need to ensure proper access to care and keep consumers on their medications. 

Genoa Healthcare’s Lindsey Hall, PharmD, BCACP, senior director of clinical programs, design and strategy and Jenn Heath, BCACP clinical quality manager, recently hosted a webinar about overcoming barriers to medication adherence during the pandemic and beyond. Below you can watch the webinar, which addresses: 

  • An update on the COVID-19 vaccine
  • Challenges and impacts related to the pandemic
  • Medication adherence amid COVID-19

To learn more about how pharmacy services can help you and your consumers, contact us today

Additional Resources

  • Convalescent plasma for treatment of COVID-19: Clinical studies are underway and while there is an Emergency Use Authorization (EUA) for use of convalescent plasma, observational studies have shown mixed results. The CDC recommends anyone who received convalescent plasma delay COVID-19 vaccination for 90 days. Click here to read more.
  • Visit https://www.genoahealthcare.com/covid19 or email [email protected] for more information.

Recent Posts


  • Behavioral Health
  • Clinical Insights
  • Treatment
Why medication-assisted treatment is essential for improving patient outcomes

1. Methadone and buprenorphine reduce risk of death after opioid overdose. (2018, June 19). NIH. 2. Methadone and buprenorphine reduce risk of death after opioid overdose. (2018, June 19). NIH....

  • 340B
Your questions, answered: 340B manufacturer pricing restrictions

Drug manufacturers began implementing restrictions for 340B pricing in 2020, citing alleged misuse by safety-net providers and explosive growth of the 340B Drug Pricing Program. Since then, restrictions for the...

  • Behavioral Health
  • Clinical Insights
  • Treatment
Currently available and emerging therapy options for treatment-resistant depression

Studies show that 50% of people with major depressive disorder don’t respond adequately to initial antidepressant treatment.1 Additionally, an estimated 30% of people with major depressive disorder (MDD) experience treatment-resistant...

  • Art Celebration
  • Consumer Stories
  • People-first Pharmacy Care
Genoa Art Celebration participant heals through art, helps others after losing daughter to substance use disorder

Content warning: This post discusses mental illness and substance use. Please call the Suicide and Crisis Lifeline at 988, the Substance Abuse and Mental Health Services Administration’s National Helpline at...